Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CBP-1019 |
Synonyms | |
Therapy Description |
CBP-1019 is a bispecific ligand-drug conjugate that targets FOLR1 (FRalpha) and TRPV6 and contains exatecan (DX-8951), which potentially inhibits tumor growth (Ann Oncol (2024) 35 (Suppl_2): S512-S513). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CBP-1019 | CBP 1019|CBP1019 | FOLR1-targeted Therapy 24 | CBP-1019 is a bispecific ligand-drug conjugate that targets FOLR1 (FRalpha) and TRPV6 and contains exatecan (DX-8951), which potentially inhibits tumor growth (Ann Oncol (2024) 35 (Suppl_2): S512-S513). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05830097 | Phase Ib/II | CBP-1019 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |